書誌事項
- タイトル別名
-
- Studies on antimicrobial activity and clinical effect of pazufloxacin
- 公開日
- 1995
- DOI
-
- 10.11250/chemotherapy1995.43.supplement2_585
- 公開者
- 公益社団法人 日本化学療法学会
この論文をさがす
説明
Bacteriological and clinical studies on pazufloxacin (PZFX), a newly developed quinolone, were carried out and the following results were obtained. The antimicrobial activity of PZFX was measured against 378 clinically isolated strains of 24 species, and compared with those of ofloxacin (OFLX), ciprofloxacin (CPFX) and fleroxacin (FLRX). The activity of PZFX was the most potent against Staphylococcus spp., and was slightly inferior to the other drugs against Streptococcus spp. The antimicrobial activity of PZFX against gram-negative bacteria was almost equal to that of CPFX and superior to those of OFLX and FLRX. Against Klebsiella pneumoniae and Xanthomonas maltophilia the activity of PZFX was the most potent.<BR>Daily doses of 300mg and 600mg were given orally 2 or 3 times to four patients with respiratory tract infection: one with pneumonia and 3 with acute bronchitis, for 3 to 13 days. Clinical response was good in 2 acute bronchitis cases and poor in the remaining 2 cases. Streptococcus pneumoniae isolated from the case with pneumonia was not eradicated. No adverse reactions were observed in any patients.
収録刊行物
-
- 日本化学療法学会雑誌
-
日本化学療法学会雑誌 43 (Supplement2), 585-590, 1995
公益社団法人 日本化学療法学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282681263446400
-
- NII論文ID
- 10005467106
- 130004297298
-
- NII書誌ID
- AN10472127
-
- ISSN
- 18845886
- 13407007
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可